nykode.com tag sponsored by:
nykode.com
-
ESMO 2024: A Phase 1 / 2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumour Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squam
nykode.com | | Article Details | Related Articles